Navigation Links
Anti-inflammatory Drug Fails to Improve COPD Symptoms

A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease//, or COPD, in a large, multi-center trial.

The results of the randomized, double-blind, placebo-controlled trial of infliximab were published in the first issue of the May American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

According to an editorial commenting on the research, the failure of the infliximab to provide any therapeutic benefit in COPD patients was unexpected because the drug has proven effective in treating other inflammatory diseases, particularly rheumatoid arthritis and Crohn's disease.

COPD is the fourth-leading cause of death of men and women in the United States and the world. It is projected to become the third-leading cause of death, after heart disease and cancer, by 2015.

Stephen I. Rennard, M.D., of the University of Nebraska Medical Center in Omaha, led a team of researchers at 41 U.S. medical centers that enrolled 234 subjects in the study. Patients receiving infliximab were randomly selected to receive the drug in doses of 3 mg/kg or 5 mg/kg six times during a six-month period of time.

At the end of six months, there was no meaningful difference in the quality of life among those taking the drug and those taking the placebo as measured by the Chronic Respiratory Questionnaire (CRQ). The questionnaire, which was the primary endpoint, assesses health-related quality of life in patients with functionally limiting chronic lung disease.

There were also no differences among the three groups in secondary efficacy endpoints as measured by FEV1, 6-minute walk distance, the transition dyspnea index and the number of exacerbations requiring a doctor or hospital visit.

According to the authors, the results of the study were surprising for a number of reasons. Infliximab is an anti-tumor necros is factor TNF-á, and a number of studies have reported increased production of TNF in COPD patients. This increased production has been linked to weight loss, muscle weakness and muscle loss.

In addition, animal studies supported the prospect using the drug in COPD. When TNF-á was infused into rats, they developed emphysema, which, along with chronic bronchitis, makes up most COPD cases. When the TNF-á receptor was turned off in mice, they were less likely than mice that had not be genetically altered to develop emphysema when exposed to chronic cigarette smoke.

The latest study, however, did confirm a recently reported pilot study that found no improvement among the 14 COPD patients given infliximab.

In attempting to explain the disappointing results, the study authors speculate that, despite infliximab's efficacy in treating other inflammatory diseases, it may not be effective in COPD because other mediators, in addition to TNF-á, are necessary to cause COPD. They also concede that six months may simply be too short a time period to see improvement.

However, an increased number of malignancies observed in infliximab-treated subjects, the authors said, raised concern about the safety of this drug in lung patients. Although the malignancies may have been present when the patients enrolled in the study, "the possibility that infliximab contributed to the progession, and thus the diagnosis, of malignancies remains a serious concern."

This safety issue, coupled with the "resoundingly negative results," make in unlikely that a longer trial will be undertaken, according to the accompanying editorial.

Source-Eurekalert
SR/B
'"/>




Related medicine news :

1. Anti-inflammatory drugs reduce the risk of oral cancer for smokers
2. Protein Secreted By Worm Eggs Holds Key To Anti-inflammatory Therapy
3. Alcoholism Drug Fails To Prevent Drinking Relapses
4. Tamiflu Fails To Save Two Lives
5. Himachal Pradesh Fails To Become Health Tourism Center
6. Budhias Medical Report Fails to Address Long Term Health Issues
7. "Daydreaming" Network Fails In Autism
8. 72-year-old Bachelor of Rajasthan Fails Class 10 Again!
9. Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project
10. NHS 24 Fails To Save a Retired Nurse
11. Smartcard Legislation Fails The Privacy Test - AMA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular ... through Molecular Imaging.” The focus of ADDMI-IG will be geared towards how using ... pipeline issues. Through ADDMI-IG WMIS will provide a platform for productive discussions about ...
(Date:5/25/2016)... ... May 25, 2016 , ... TransactRx ... real time adjudication of medical service claims by Pharmacy Benefit Managers that were ... claims management software. The TransactRx Cross Benefit Clearinghouse receives standard professional medical claims ...
(Date:5/25/2016)... ... , ... For more than fifty years, we've suffered whiplash as each new scientific study seemed ... the latest nutritional advice – advice that was supposed to keep us healthy and slim. ... American adults are considered to be overweight and more than 1 in 3 adults are ...
(Date:5/25/2016)... ... May 25, 2016 , ... Consumer access to organic foods and ... Kashi®, a maker of whole grain cereals and other plant-based foods, will introduce the ... hard red winter wheat processed by Hesco/Dakota Organic Products. , The transitional designation means ...
(Date:5/24/2016)... ... May 24, 2016 , ... According to an article published ... randomly assigned to reduce the amount of calories they consumed by 25% experienced some ... weight enjoyed better sleep, improved quality of life, and enhanced sexual function compared to ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... OXFORD, England , May 24, 2016 ... Practice and Education in Clinical Neurophysiology  ... medical information products and services, today announced the launch ... , an open access journal that focuses on clinical ... latest research, case reports, clinical series, normal values and ...
(Date:5/23/2016)... India , May 23, 2016 ... report "Patient Handling Equipment Market by Product (Wheelchair, ... of Care (Bariatric Care, Critical Care, Wound), Accessories ... - Forecast to 2021", published by MarketsandMarkets, the ... USD 17.18 Billion by 2021 at a CAGR ...
(Date:5/23/2016)... 23, 2016 Transparency Market Research ... Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, ... to the report, the exocrine pancreatic insufficiency market is ... 2015 to 2023 to reach US$2.85 Bn by 2023. ... characterized by the deficiency of the exocrine pancreatic enzymes, ...
Breaking Medicine Technology: